The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cataplexy


Psychiatry related information on Cataplexy


High impact information on Cataplexy

  • We now report that, in contrast to these other monoaminergic "REM-off" cell groups, histamine neurons are active in cataplexy at a level similar to or greater than that in quiet waking [4].
  • Treatment of narcoleptic dogs with 25-600 micrograms/kg prazosin, a selective alpha-1 adrenergic receptor blocker, exacerbated cataplexy, whereas treatment with the alpha-1 agonist, methoxamine, ameliorated it [9].
  • The role of central alpha-1 adrenergic receptors in cataplexy was investigated in genetically narcoleptic Doberman pinschers [9].
  • Clomipramine and clonazepam in cataplexy [10].
  • The treatment of narcoleptic dogs with PGE2 and PGE2 methyl ester, but not PGD2 and PGD2 methyl ester, induced a dose-dependent reduction of canine cataplexy, a dissociated manifestation of rapid-eye-movement sleep [6].

Chemical compound and disease context of Cataplexy


Biological context of Cataplexy


Anatomical context of Cataplexy


Gene context of Cataplexy

  • Cataplexy and monoamine oxidase deficiency in Norrie disease [20].
  • Using hypocretin receptor 2 gene (hcrtr 2)-mutated narcoleptic Dobermans, we have previously demonstrated that altered dopamine (DA) D(2/3) receptor mechanisms in mesencephalic DA nuclei are important for the induction of cataplexy [21].
  • This unusual entity differs from startle epilepsy and cataplexy [22].
  • Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy [23].
  • Other clinical and polygraphic findings may indicate that young age at onset is associated with increased severity of the condition (higher frequency of cataplexy and decreased mean sleep latency on the Multiple Sleep Latency Test) [24].

Analytical, diagnostic and therapeutic context of Cataplexy


  1. Carbamazepine as a treatment for cataplexy. Vaughn, B.V., D'Cruz, O.F. Sleep. (1996) [Pubmed]
  2. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Anic-Labat, S., Guilleminault, C., Kraemer, H.C., Meehan, J., Arrigoni, J., Mignot, E. Sleep. (1999) [Pubmed]
  3. Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult. Lagrange, A.H., Blaivas, M., Gomez-Hassan, D., Malow, B.A. Epilepsy & behavior : E&B. (2003) [Pubmed]
  4. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. John, J., Wu, M.F., Boehmer, L.N., Siegel, J.M. Neuron (2004) [Pubmed]
  5. Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial. Elwes, R.D., Crewes, H., Chesterman, L.P., Summers, B., Jenner, P., Binnie, C.D., Parkes, J.D. Lancet (1989) [Pubmed]
  6. Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Nishino, S., Mignot, E., Fruhstorfer, B., Dement, W.C., Hayaishi, O. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  7. Effect of genetically caused excess of brain gamma-hydroxybutyric acid and GABA on sleep. Arnulf, I., Konofal, E., Gibson, K.M., Rabier, D., Beauvais, P., Derenne, J.P., Philippe, A. Sleep. (2005) [Pubmed]
  8. Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in Long-Evans rats. Gerashchenko, D., Blanco-Centurion, C., Greco, M.A., Shiromani, P.J. Neuroscience (2003) [Pubmed]
  9. Role of central alpha-1 adrenoceptors in canine narcolepsy. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., Dement, W.C. J. Clin. Invest. (1988) [Pubmed]
  10. Clomipramine and clonazepam in cataplexy. Parkes, J.D., Schachter, M. Lancet (1979) [Pubmed]
  11. Pharmacological aspects of human and canine narcolepsy. Nishino, S., Mignot, E. Prog. Neurobiol. (1997) [Pubmed]
  12. Monoaminergic mechanisms and experimental cataplexy. Foutz, A.S., Delashaw, J.B., Guilleminault, C., Dement, W.C. Ann. Neurol. (1981) [Pubmed]
  13. Dopamine D2 mechanisms in canine narcolepsy. Nishino, S., Arrigoni, J., Valtier, D., Miller, J.D., Guilleminault, C., Dement, W.C., Mignot, E. J. Neurosci. (1991) [Pubmed]
  14. Sodium oxybate for cataplexy. Lemon, M.D., Strain, J.D., Farver, D.K. The Annals of pharmacotherapy. (2006) [Pubmed]
  15. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. Fronczek, R., Lammers, G.J., Balesar, R., Unmehopa, U.A., Swaab, D.F. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  16. Cholinergic mechanisms in canine narcolepsy--II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. Reid, M.S., Siegel, J.M., Dement, W.C., Mignot, E. Neuroscience (1994) [Pubmed]
  17. Locus coeruleus neurons: cessation of activity during cataplexy. Wu, M.F., Gulyani, S.A., Yau, E., Mignot, E., Phan, B., Siegel, J.M. Neuroscience (1999) [Pubmed]
  18. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Gulyani, S., Wu, M.F., Nienhuis, R., John, J., Siegel, J.M. Neuroscience (2002) [Pubmed]
  19. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected]. Honda, K., Riehl, J., Mignot, E., Nishino, S. Neuroreport (1999) [Pubmed]
  20. Cataplexy and monoamine oxidase deficiency in Norrie disease. Vossler, D.G., Wyler, A.R., Wilkus, R.J., Gardner-Walker, G., Vlcek, B.W. Neurology (1996) [Pubmed]
  21. The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Okura, M., Fujiki, N., Kita, I., Honda, K., Yoshida, Y., Mignot, E., Nishino, S. Neurobiol. Dis. (2004) [Pubmed]
  22. Hyperekplexia: a syndrome of pathological startle responses. Sáenz-Lope, E., Herranz-Tanarro, F.J., Masdeu, J.C., Chacón Peña, J.R. Ann. Neurol. (1984) [Pubmed]
  23. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. Nishino, S., Arrigoni, J., Shelton, J., Kanbayashi, T., Dement, W.C., Mignot, E. J. Neurosci. (1997) [Pubmed]
  24. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Dauvilliers, Y., Montplaisir, J., Molinari, N., Carlander, B., Ondze, B., Besset, A., Billiard, M. Neurology (2001) [Pubmed]
  25. Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Reid, M.S., Tafti, M., Nishino, S., Siegel, J.M., Dement, W.C., Mignot, E. Sleep. (1994) [Pubmed]
  26. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Riehl, J., Honda, K., Kwan, M., Hong, J., Mignot, E., Nishino, S. Neuropsychopharmacology (2000) [Pubmed]
  27. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Black, J.L., Silber, M.H., Krahn, L.E., Fredrickson, P.A., Pankratz, V.S., Avula, R., Walker, D.L., Slocumb, N.L. Sleep. (2005) [Pubmed]
  28. Benefits and risks of pharmacotherapy for narcolepsy. Mitler, M.M., Hayduk, R. Drug safety : an international journal of medical toxicology and drug experience. (2002) [Pubmed]
  29. Novel chromosomal abberation in a patient with a unique sleep disorder. Hasegawa, Y., Morishita, M., Suzumura, A. J. Neurol. Neurosurg. Psychiatr. (1998) [Pubmed]
WikiGenes - Universities